(IN BRIEF) GSK and the University of Cambridge have announced a £50 million, five-year collaboration called the Cambridge-GSK Translational Immunology Collaboration (CG-TIC) to accelerate research and development in kidney and respiratory diseases. The initiative combines GSK’s expertise in immunology and … Read the full press release
Posted in Artificial Intelligence (AI), Business, Education, Financial, Healthcare, Industrial, Investment, Management, News, Pharma & Biotech, Science, Security & Safety, Technology, United Kingdom
Tagged AI, Cambridge University, Cambridge-GSK Translational Immunology Collaboration (CG-TIC), GSK, immunology, investment, Kidney and Respiratory Diseases, Nicolas Wisniacki, partnership, Peter Kyle, Professor David Thomas, safety, sustainability, Tony Wood
(IN BRIEF) GSK plc has announced positive results from its Phase III ANCHOR trials for depemokimab, a biologic treatment for chronic rhinosinusitis with nasal polyps (CRSwNP). The trials demonstrated a significant reduction in nasal polyp size and nasal obstruction after … Read the full press release
Posted in Business, Financial, Healthcare, Industrial, Investment, Management, News, Pharma & Biotech, Science, Security & Safety, Technology, United Kingdom
Tagged chronic rhinosinusitis, Depemokimab, GSK, Kaivan Khavandi, Nasal Polyps, safety
(IN BRIEF) GSK has reported positive results from its phase II trial for an mRNA seasonal influenza vaccine candidate, showing strong immune responses against influenza A and B strains in both younger and older adults. The trial met success criteria … Read the full press release
Posted in Business, Financial, Industrial, Investment, Management, News, Pharma & Biotech, Science, Security & Safety, Technology, United Kingdom
Tagged flu vaccine, GSK, mRNA, Phase II, Phase III, safety, Tony Wood
(IN BRIEF) GSK’s depemokimab, a new ultra-long-acting biologic, showed a 54% reduction in severe asthma exacerbations in the SWIFT-1 and SWIFT-2 phase III trials. Administered every six months, it also demonstrated a 72% reduction in hospitalizations and emergency visits, offering … Read the full press release
Posted in Business, Financial, Healthcare, Industrial, Investment, Management, News, Pharma & Biotech, Science, Security & Safety, Technology, United Kingdom
Tagged David Jackson, Depemokimab, GSK, Phase III Trials, safety, Severe Asthma Attacks, SWIFT-1, SWIFT-2
(IN BRIEF) GSK will present significant research at the 2024 European Respiratory Society (ERS) Congress, including data from phase III trials of its new biologic, depemokimab, for severe asthma. The presentations highlight GSK’s commitment to advancing respiratory medicine, with a … Read the full press release
(IN BRIEF) The Conference Forum announced the launch of the 8th annual Patients as Partners® Europe meeting, scheduled for May 14-15, 2024, at Plaisterers’ Hall in London, England. This event brings together pharma R&D and patient advocacy to discuss patient … Read the full press release
Posted in Healthcare, Marketing, Pharma & Biotech, United Kingdom
Tagged 8th annual Patients as Partners® Europe, AbbVie, Anders Lassen, Andrew Garvey, Annie Gilbert, Astellas, AstraZeneca, Biotech, Boehringer Ingelheim, clinical operations, clinical research, clinical trials, Conference, David James, decentralized clinical trials, Derek Stewart, diversifying clinical trials, diversity, drug development, England, GSK, Health Equity, inclusivity, inclusivity in clinical research, Ipsen, LGBTQ+ oncology, Lisa Kerr, London, Lundbeck, Novartis, Novo Nordisk, Oleksandr Gorbenko, Parexel, Patient Advocacy, patient engagment, patient experience mapping, Patrick Gallogly, Pfizer, pharma, Plaisterers’ Hall, Prostate Cancer Research, Rosamund Round, Sanofi, Sarah Zenner Dolan, Stephen Head, The Conference Forum, Valerie Bowling, Victoria DiBiaso, , Alfred Samuel
(IN BRIEF) GSK has announced encouraging findings from the interim analysis of the DREAMM-8 phase III trial evaluating Blenrep (belantamab mafodotin) in combination with pomalidomide plus dexamethasone (PomDex) compared to the standard of care, bortezomib plus PomDex, for relapsed or … Read the full press release
(IN BRIEF) GSK plc has announced positive headline results from the pivotal EAGLE-1 phase III trial for gepotidacin, an oral antibiotic aimed at treating uncomplicated urogenital gonorrhoea in adolescents and adults. The trial demonstrated gepotidacin’s non-inferiority compared to the current … Read the full press release
(IN BRIEF) GSK plc has finalized the acquisition of Aiolos Bio, bolstering its respiratory biologics portfolio with AIO-001, a promising long-acting anti-TSLP monoclonal antibody for treating asthma. AIO-001, set to enter phase II clinical trials, targets severe asthma patients with … Read the full press release
Posted in Business, Financial, Healthcare, Industrial, Investment, Management, News, Pharma & Biotech, Science, Technology, United Kingdom
Tagged acquisition, Aiolos Bio, biologics, GSK, respiratory, Tony Wood
(IN BRIEF) GSK plc has announced that the US Food and Drug Administration (FDA) has granted Fast Track designation for bepirovirsen, an investigational antisense oligonucleotide (ASO) targeting chronic hepatitis B (CHB). The Fast Track designation aims to expedite the development … Read the full press release
Posted in Business, Education, Financial, Government, Healthcare, Industrial, Investment, Management, News, Pharma & Biotech, Science, Technology, United Kingdom
Tagged Bepirovirsen, Chronic Hepatitis B Treatment, FDA Fast Track, GSK
(IN BRIEF) GSK has received marketing authorization from the European Commission for Omjjara (momelotinib), an oral inhibitor targeting JAK1/JAK2 and activin A receptor type 1 (ACVR1). Omjjara is the first approved treatment in the EU for disease-related splenomegaly (enlarged spleen) … Read the full press release
Posted in Business, Education, Financial, Healthcare, Industrial, Investment, Management, News, Pharma & Biotech, Science, Technology, United Kingdom
Tagged Francesca Palandri, GSK, Myelofibrosis Treatment, Nina Mojas, Omjjara, splenomegaly
(IN BRIEF) GSK has submitted a regulatory application to the European Medicines Agency (EMA) to expand the use of its adjuvanted recombinant respiratory syncytial virus (RSV) vaccine to adults aged 50-59 who are at increased risk for RSV disease. The … Read the full press release
Posted in Business, Education, Financial, Healthcare, Industrial, Investment, Management, News, Pharma & Biotech, Science, Technology, United Kingdom
Tagged Adults Aged 50-59, COPD, GSK, NCT05590403, RSV Vaccination, vaccine
(IN BRIEF) GSK plc has announced positive results from Part 2 of the RUBY/ENGOT-EN6/GOG3031/NSGO phase III trial, evaluating the use of Jemperli (dostarlimab) in combination with standard chemotherapy and as maintenance therapy for patients with primary advanced or recurrent endometrial … Read the full press release
Posted in Business, Healthcare, Industrial, Management, News, Pharma & Biotech, Science, Technology, United Kingdom
Tagged chomotherapy, dostarlimab, Endometrial Cancer Trial, GSK, Hesham Abdullah, RUBY, Zejula
(IN BRIEF) In a significant development, GSK plc has received marketing authorization from the European Commission (EC) for Jemperli (dostarlimab) in combination with carboplatin-paclitaxel chemotherapy as a treatment option for adult patients suffering from mismatch repair deficient (dMMR)/microsatellite instability-high (MSI-H) … Read the full press release
(IN BRIEF) GlaxoSmithKline (GSK) has reported positive results from the interim efficacy analysis of the DREAMM-7 phase III trial evaluating belantamab mafodotin as a second-line treatment for relapsed or refractory multiple myeloma. The trial successfully met its primary endpoint of … Read the full press release
(IN BRIEF) GSK, a leading pharmaceutical company, has unveiled plans to conduct Phase III trials in 2024 for a low carbon version of its popular inhaler, Ventolin (salbutamol). The initiative aims to reduce greenhouse gas emissions associated with the inhaler’s … Read the full press release
Posted in Business, Environment, Healthcare, Industrial, Management, News, Pharma & Biotech, Science, Technology, United Kingdom
Tagged emissions, Emma Walmsley, GSK, health, Low Carbon Inhaler, respiratory conditions, sustainability, Ventolin
(IN BRIEF) ViiV Healthcare has received approval from China’s National Medical Products Administration (NMPA) for Vocabria (cabotegravir) in combination with Rekambys (rilpivirine), marking the first complete long-acting HIV-1 injectable treatment in China. This approval allows people living with HIV in … Read the full press release
Posted in Business, Environment, Financial, Government, Healthcare, Industrial, Investment, Management, News, Pharma & Biotech, Science, Technology, United Kingdom
Tagged cabotegravir, CHINA, Chinese Approval, Deborah Waterhouse, GSK, HIV, injection, partnership, Pfizer, Rekambys, rilpivirine, Shionogi, sustainability, treatment, ViiV Healthcare, Vocabria
(IN BRIEF) ViiV Healthcare, a global specialist HIV company, will present 23 abstracts at the 19th Annual European AIDS Conference (EACS 2023). These abstracts will cover various aspects of HIV treatment and prevention, including real-world data on long-acting and 2-drug … Read the full press release
Posted in Business, Education, Financial, Healthcare, Industrial, Investment, Management, Media, News, Pharma & Biotech, Science, Technology, United Kingdom
Tagged Apretude, Dovato, EACS 2023, GSK, HIV, Kimberly Smith, partnership, Pfizer, prevention, Rekambys, Rukobia, Shionogi, treatment, ViiV Healthcare, Vocabria
(IN BRIEF) GSK has received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) for the approval of Jemperli (dostarlimab) in combination with chemotherapy as a frontline treatment for adult … Read the full press release
Posted in Business, Education, Healthcare, Industrial, Management, News, Pharma & Biotech, Science, Technology, United Kingdom
Tagged chemotherapy, CHMP, dostarlimab, endometrial cancer, GSK, Hesham Abdullah, Jemperli, RUBY, treatment
(IN BRIEF) Lloyds Banking Group has appointed Suresh Balaji as its Chief Marketing Officer, effective from October 16. In his new role, Balaji will oversee the Brand, Marketing, and Experience function for the group. He will be responsible for developing … Read the full press release
Posted in Banks, Business, Financial, Marketing, United Kingdom
Tagged appointment, GSK, leadership, Lloyds Banking Group, marketing, Standard Chartered Bank, Suresh Balaji, United Breweries, WPP
EuropaWire (EW) is the first truly pan-European and leading press release distribution and newswire service for Europe and the European Union working towards consolidating Europe’s voice on the global newswire and media scene. The newswire service comes with advanced submission forms, flexible pricing and PR budgeting, granular targeting, nearly uncapped reach across countries, markets, verticals, industries, audiences, languages, etc., translation and localisation for greater local PR impact, in-depth distribution reporting, metrics and insights including measured PR reach, reads, engagements, impact, etc., no cap on words, images and multimedia to go along with your release, among others. Your press releases will be seen among the releases of Europe’s biggest and most prominent companies, brands and institutions.
HOW TO GET STARTED?